Cas:1207456-00-5 BMN-673 (8R,9S) manufacturer & supplier

We serve Chemical Name:BMN-673 (8R,9S) CAS:1207456-00-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

BMN-673 (8R,9S)

Chemical Name:BMN-673 (8R,9S)
CAS.NO:1207456-00-5
Synonyms:(8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;BMN-673 8R,9S||BMN673 (8R,9S)|BMN 673 (8R,9S);BMN 673 (8R,9S);CS-1223;BMN-673 (8R,9S)
Molecular Formula:C19H14F2N6O
Molecular Weight:380.35100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:91.98000
Exact Mass:380.12000
LogP:1.89830

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,BMN-673 (8R,9S) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,BMN-673 (8R,9S) Use and application,(8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one technical grade,usp/ep/jp grade.


Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. Luciferin-6′-benzyl ether manufacturers Contract research organisation Charles River Laboratories International Inc. today announced plans for an €8M expansion of its testing capabilities at its Ballina, Co. Mayo site that will give an additional 1,500m2 of lab space and create up to 90 new skilled roles over the next three years. 5-(but-3-enamido)-3-(tert-butyl)-N,N-dimethyl-1H-pyrazole-1-carboxamide suppliers AstraZeneca’s application for anifrolumab in SLE is under review by regulatory authorities in the US, EU and Japan, with decisions anticipated in the second half of 2021. Anifrolumab is not currently approved in any country. 4-(3-amino-5-bromo-pyridin-2-ylimino)-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one vendor & factory.